• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A predictor of response in HER2+ breast cancer-at last!终于找到了HER2阳性乳腺癌治疗反应的预测指标！
J Natl Cancer Inst. 2023 Mar 9;115(3):242-245. doi: 10.1093/jnci/djac228.
2
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.HER2 与 CEP17 比值在接受曲妥珠单抗或不接受曲妥珠单抗新辅助化疗的非转移性 HER2 阳性炎性和非炎性乳腺癌患者中荧光原位杂交比值的预后价值。
Oncologist. 2020 Jun;25(6):e909-e919. doi: 10.1634/theoncologist.2018-0611. Epub 2020 Jan 31.
3
Rate of pathological complete response in early HER2 breast cancer.
Bull Cancer. 2022 Jun;109(6):722-723. doi: 10.1016/j.bulcan.2022.02.016. Epub 2022 May 11.
4
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).帕妥珠单抗/曲妥珠单抗/化疗与曲妥珠单抗/化疗用于 HER2+乳腺癌：前瞻性新辅助乳腺注册研究 SYMPHONY 试验的结果（NBRST）。
Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. Epub 2017 Apr 26.
5
Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.新辅助治疗中接受曲妥珠单抗治疗的HER2阳性乳腺癌患者的病理完全缓解
J Coll Physicians Surg Pak. 2019 Feb;29(2):159-163. doi: 10.29271/jcpsp.2019.02.159.
6
Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.新辅助治疗 HER2+乳腺癌的双 HER2 阻断：荟萃分析和综述。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820960721. doi: 10.1177/1533033820960721.
7
Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.在人表皮生长因子受体2（HER2）扩增的乳腺癌中，新辅助曲妥珠单抗和帕妥珠单抗治疗的病理完全缓解与HER2扩增水平相关。
Medicine (Baltimore). 2020 Nov 13;99(46):e23053. doi: 10.1097/MD.0000000000023053.
8
[Not Available].[无可用内容]
Bull Cancer. 2016 Jun;103(6 Suppl 1):S76-89. doi: 10.1016/S0007-4551(16)30149-7.
9
Neoadjuvant Chemotherapy in Synchronous Bilateral Breast Cancer With Different HER2 Types.
Am J Ther. 2021;28(6):e769-e772. doi: 10.1097/MJT.0000000000000895.
10
[The Efficacy of Combined Use of Pertuzumab and Trastuzumab-Based Neoadjuvant Chemotherapy for HER2 Positive Breast Cancer].
Gan To Kagaku Ryoho. 2021 Dec;48(13):1822-1824.

本文引用的文献

1
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.T-DM1 治疗的晚期 HER2 阳性乳腺癌中 HER2DX 和 ERBB2 mRNA 表达。
J Natl Cancer Inst. 2023 Mar 9;115(3):332-336. doi: 10.1093/jnci/djac227.
2
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.曲妥珠单抗和帕妥珠单抗新辅助治疗后 HER2 阳性/激素受体阳性乳腺癌的 HER2DX 基因组检测：来自 PerELISA 试验的相关性分析。
EBioMedicine. 2022 Nov;85:104320. doi: 10.1016/j.ebiom.2022.104320. Epub 2022 Oct 29.
3
Targeting HER2-positive breast cancer: advances and future directions.针对 HER2 阳性乳腺癌：进展与未来方向。
Nat Rev Drug Discov. 2023 Feb;22(2):101-126. doi: 10.1038/s41573-022-00579-0. Epub 2022 Nov 7.
4
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.玛妥昔单抗对比曲妥珠单抗治疗既往接受过治疗的 HER2 阳性晚期乳腺癌患者（SOPHIA）：一项随机 III 期试验的最终总生存结果。
J Clin Oncol. 2023 Jan 10;41(2):198-205. doi: 10.1200/JCO.21.02937. Epub 2022 Nov 4.
5
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.比较 HercepTest™ mAb pharmDx（Dako Omnis，GE001）与乳腺癌中的 Ventana PATHWAY 抗 HER-2/neu（4B5）：与 HER2 扩增和 HER2 低状态的相关性。
Virchows Arch. 2022 Nov;481(5):685-694. doi: 10.1007/s00428-022-03378-5. Epub 2022 Aug 16.
6
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.曲妥珠单抗-德曲妥珠单抗用于既往治疗的 HER2 低表达晚期乳腺癌。
N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
7
Role of Fcγ receptors in HER2-targeted breast cancer therapy.Fcγ 受体在曲妥珠单抗治疗 HER2 阳性乳腺癌中的作用
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003171.
8
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.用于预测早期HER2阳性乳腺癌病理反应和生存结果的新型HER2DX检测方法的开发与验证
EBioMedicine. 2022 Jan;75:103801. doi: 10.1016/j.ebiom.2021.103801. Epub 2022 Jan 3.
9
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.在 MARIANNE 研究中，曲妥珠单抗-美坦新偶联物±帕妥珠单抗对比曲妥珠单抗联合紫杉烷类用于 HER2 阳性晚期乳腺癌的 III 期研究中，肿瘤标志物与疗效的关系。
BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0.
10
Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.免疫组化/荧光原位杂交（IHC/FISH）法检测 ER、PR、HER2 和 Ki67 与基于自动化、广泛应用的诊断平台的 RT-qPCR 法检测相应的 mRNAs（ESR1、PGR、ERBB2 和 MKI67）的中心实验室评估比较。
Breast Cancer Res Treat. 2018 Nov;172(2):327-338. doi: 10.1007/s10549-018-4889-5. Epub 2018 Aug 17.

A predictor of response in HER2+ breast cancer-at last!

作者信息

Badve Sunil S, Gökmen-Polar Yesim

机构信息

Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.

出版信息

J Natl Cancer Inst. 2023 Mar 9;115(3):242-245. doi: 10.1093/jnci/djac228.

DOI:10.1093/jnci/djac228
PMID:36576003
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9996198/
Abstract
摘要